Danaher (NYSE:DHR) Price Target Increased to $315.00 by Analysts at TD Cowen

Danaher (NYSE:DHR) had its price objective hoisted by TD Cowen from $310.00 to $315.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the conglomerate’s stock.

A number of other equities analysts have also commented on the stock. Evercore ISI boosted their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Wells Fargo & Company initiated coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective on the stock. Barclays dropped their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday. Stephens reissued an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research report on Wednesday. Finally, UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Stock Performance

NYSE:DHR opened at $245.39 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $181.76 billion, a price-to-earnings ratio of 41.59, a PEG ratio of 4.49 and a beta of 0.83. The firm’s fifty day simple moving average is $269.52 and its 200 day simple moving average is $260.42. Danaher has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business posted $2.02 EPS. The business’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, equities research analysts expect that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insiders Place Their Bets

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,059 shares of company stock worth $8,400,897. Insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

A number of institutional investors have recently made changes to their positions in the stock. Hudson Valley Investment Advisors Inc. ADV lifted its stake in Danaher by 22.7% during the third quarter. Hudson Valley Investment Advisors Inc. ADV now owns 46,106 shares of the conglomerate’s stock valued at $12,818,000 after purchasing an additional 8,526 shares during the last quarter. SteelPeak Wealth LLC lifted its stake in Danaher by 5.7% during the third quarter. SteelPeak Wealth LLC now owns 1,420 shares of the conglomerate’s stock valued at $395,000 after purchasing an additional 76 shares during the last quarter. ADE LLC acquired a new stake in Danaher during the third quarter valued at approximately $206,000. Pinnacle Associates Ltd. lifted its stake in Danaher by 4.6% during the third quarter. Pinnacle Associates Ltd. now owns 24,927 shares of the conglomerate’s stock valued at $6,930,000 after purchasing an additional 1,091 shares during the last quarter. Finally, First Trust Direct Indexing L.P. lifted its stake in Danaher by 7.1% during the third quarter. First Trust Direct Indexing L.P. now owns 17,925 shares of the conglomerate’s stock valued at $4,984,000 after purchasing an additional 1,186 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.